CING (Cingulate) Short-Term Debt: $6.15 Mil (As of Mar. 2026)


CING Cingulate Inc CING
36 GF Score
Price $5.38
! 1 Warning Sign
View Full Analysis

What is Cingulate Short-Term Debt?

Cingulate CING -8.81% 36 Short-Term Debt is $6.15 Mil as of Mar. 2026. GuruFocus rates CING with a GF Score™ of 36/100. The stock has 1 warning sign investors should review.

Cingulate's Short-Term Debt for the quarter that ended in Mar. 2026 was $6.15 Mil.

Cingulate's quarterly Short-Term Debt increased from Sep. 2025 ($3.19 Mil) to Dec. 2025 ($6.30 Mil) but then declined from Dec. 2025 ($6.30 Mil) to Mar. 2026 ($6.15 Mil).

Cingulate's annual Short-Term Debt declined from Dec. 2023 ($3.00 Mil) to Dec. 2024 ($2.53 Mil) but then increased from Dec. 2024 ($2.53 Mil) to Dec. 2025 ($6.30 Mil).

Cingulate Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Cingulate Short-Term Debt Related Terms

Cingulate Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Cingulate's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cingulate Short-Term Debt Chart

Cingulate Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.00 5.00 3.00 2.53 6.30

Cingulate Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.13 5.13 3.19 6.30 6.15
CING
36GF Score
Cingulate Inc CING
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $6.15 Mil mean?
Cingulate (CING) has a Short-Term Debt of $6.15 Mil as of Mar. 2026.
Is Cingulate's Short-Term Debt too high?
Cingulate's current Short-Term Debt is $6.15 Mil. Overall, Cingulate has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Cingulate's Short-Term Debt compare to IMA and MCRB?
Cingulate's Short-Term Debt of $6.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Cingulate's current Short-Term Debt is $6.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cingulate stock overvalued right now?
Cingulate (CING) has a current Short-Term Debt of $6.15 Mil. The current Short-Term Debt is $6.15 Mil. Cingulate's overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Cingulate (CING), the current Short-Term Debt is $6.15 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cingulate Business Description

Address 1901 West 47th Place, Kansas, KS, USA, 66205
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
36GF Score

Get the complete analysis for CING

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.38
Price